146 related articles for article (PubMed ID: 36892677)
1. Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
de Jong LAW; Lambert M; van Erp NP; de Vries L; Chatelut E; Ottevanger PB
Cancer Chemother Pharmacol; 2023 Mar; 91(3):247-256. PubMed ID: 36892677
[TBL] [Abstract][Full Text] [Related]
2. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA; Grisham RN; O'Cearbhaill RE; Boucicaut NN; Henson M; Iasonos A; Zhou Q; Sarasohn DM; Gallagher J; Kravetz S; Zamarin D; Makker V; Sabbatini PJ; Tew WP; Aghajanian C; Konner JA
Gynecol Oncol; 2020 Apr; 157(1):214-221. PubMed ID: 31959492
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
5. Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.
Chen KJ; Chen WY; Chen X; Jia YM; Peng GQ; Chen L
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):25-31. PubMed ID: 23681836
[TBL] [Abstract][Full Text] [Related]
6. Optimizing regional chemotherapy for epithelial ovarian cancer.
Sugarbaker PH
J Obstet Gynaecol Res; 2022 Jun; 48(6):1306-1317. PubMed ID: 35343033
[TBL] [Abstract][Full Text] [Related]
7. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Dizon DS; Sill MW; Gould N; Rubin SC; Yamada SD; Debernardo RL; Mannel RS; Eisenhauer EL; Duska LR; Fracasso PM
Gynecol Oncol; 2011 Nov; 123(2):182-6. PubMed ID: 21820161
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of advanced ovarian cancer: current status and future directions.
Ozols RF; Vermorken JB
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
[TBL] [Abstract][Full Text] [Related]
9. Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
Chang YH; Lu CH; Yen MS; Lee WH; Chang Y; Chang WP; Chuang CM
Chin J Cancer; 2016 May; 35():45. PubMed ID: 27160669
[TBL] [Abstract][Full Text] [Related]
10. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
Ansaloni L; Coccolini F; Morosi L; Ballerini A; Ceresoli M; Grosso G; Bertoli P; Busci LM; Lotti M; Cambria F; Pisano M; Rossetti D; Frigerio L; D'Incalci M; Zucchetti M
Br J Cancer; 2015 Jan; 112(2):306-12. PubMed ID: 25461804
[TBL] [Abstract][Full Text] [Related]
13. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
16. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
17. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
19. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]